Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 43 Genitourinary 43 Other solid neoplasm 13 Gastrointestinal 12 Gynecologic 11 Thoracic 10 Head & Neck 9 Breast 9 Tumor-Agnostic 6 Dermatologic 4 CNS 4 Endocrine 3 NET 2 Plasma cell 1 Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 678 Cytarabine 576 fludarabine 410 fludarabine phosphate 387 venetoclax 310 Methotrexate 297 Rituximab 283 Azacitidine 264 Busulfan 248 Whole-Body Irradiation 220 Etoposide 215 Filgrastim 214 Peripheral Blood Stem Cell Transplantation 211 Mycophenolic Acid 206 Tacrolimus 196 Dexamethasone 191 Granulocyte Colony-Stimulating Factor 182 Vincristine 173 Melphalan 173 Decitabine 163 Cyclosporine 146 Daunorubicin 139 Antilymphocyte Serum 137 Idarubicin 134 Imatinib Mesylate 127 Lenalidomide 116 Doxorubicin 109 Radiotherapy 108 Stem Cell Transplantation 107 Clofarabine 106

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × pazopanib × Other hematologic neoplasm × Clear all

NCT01361334 2021-04-08

PAZOPANIB-AML

University Hospital Muenster

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡